Another Tuesday, another FDA approval for GSK. The European drug giant picked up accelerated approval for Nelkarmi (neladalkib) in locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). It is the second lung cancer green light for GSK Plc. (GSK) this year, which is a nice way to start a Wednesday.
The approval covers patients who have already been through the treatment wringer. Specifically, regulators cleared the kinase inhibitor for those who previously received either one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or two or more prior ALK TKIs alongside platinum-based chemotherapy in the unresectable locally advanced or metastatic setting.
Clinical Trial Results Show Durable Responses
The FDA leaned on the Phase 1/2 ALKOVE-1 trial, which showed clinically meaningful and durable responses in pretreated patients. Investigators split the efficacy analysis into two patient groups to assess confirmed overall response rate (CRR) and duration of response (DOR).
Among 67 patients who previously received one ALK TKI consisting of alectinib in the metastatic setting, neladalkib achieved a 49% ORR. Within that responding group, 76% maintained a DOR of at least six months, and 52% held on for at least 12 months.
Among 155 patients who previously received two or more ALK TKIs and platinum-based chemotherapy, treatment produced a 32% ORR. Of those responders, 69% achieved a DOR of at least six months, while 51% reached the 12-month mark.
GSK didn't discover this drug in its own labs. It added the asset via a Nuvalent deal worth $10.6 billion. That acquisition handed GSK three lung cancer assets in a single transaction, including Nuvalent's lead drug candidates, zidesamtinib and neladalkib, both being developed for certain forms of non-small cell lung cancer.
So the $10.6 billion check is already starting to look less like a gamble and more like a down payment on a pipeline. One approval down, and the rest of the Nuvalent haul still has room to run.
GSK Price Action: GSK shares were up 0.12% at $49.30 at the time of publication on Wednesday, according to market data.